Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ERYtech Pharma has announced the inclusion of its last patient in its Phase II clinical trial for relapsed acute lymphoblastic leukemia.
Subscribe to our email newsletter
The main goal of this trial is to evaluate the pharmacokinetic, the pharmacodynamic and the safety of Graspa, ERYtech Pharma’s new medicinal product.
Approximately 24 patients comprised of nine adults and nine children received at least one dose of Graspa, three other children and three adult patients received the control product, the free form of native E coli L-Asparaginase.
ERYtech Pharma has also announced that it has elected the Philadelphia University Science Center as their US operations base.
David Liens, chief medical officer of ERYtech Pharma, said: “The first results will be known in three months time. A development strategy for patients with intolerance to other forms of asparaginases will be rapidly initiated.”